<DOC>
	<DOC>NCT01941199</DOC>
	<brief_summary>This is a randomized, open-label, multiple dosing, three-way crossover clinical trial to investigate the pharmacokinetic/pharmacodynamic drug-drug interaction of DA-1229 5 mg and Metformin IR 1000 mg after oral administration in healthy male volunteers.</brief_summary>
	<brief_title>Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Age between 20 to 45, healthy male subjects(at screening) Body weight between 55kg 90kg, BMI between 18.0 27.0 FPG 70125mg/dL glucose level(at screening) Subject who totally understand the progress of this clinical trials, make decision by his free will, and signed a consent form to follow the progress. Subject who has past or present history of any diseases following below.(liver including hepatitis virus carrier, kidney, Neurology, immunology, pulmonary, endocrine, hematooncology, cardiology, mental disorder) Subject who had GI tract disease(Crohn's disease, ulcer, acute or chronic pancreatitis) or surgery(appendectomy, hernioplasty are excluded) Subject who had drug(Aspirin, antibiotics) hypersensitivity reaction Subject who already participated in other trials in 2 months Subject who had whole blood donation in 2 months, or component blood donation in 1 months or transfusion in 1 months currently.</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>